Thomas J Stopka, Denise C Babineau, Erin B Gibson, Charles E Knott, Debbie M Cheng, Jennifer Villani, Jonathan M Wai, Derek Blevins, James L David, Dawn A Goddard-Eckrich, Michelle R Lofwall, Richard Massatti, Jolene DeFiore-Hyrmer, Michael S Lyons, Laura C Fanucchi, Daniel R Harris, Jeffery Talbert, Lindsey Hammerslag, Devin Oller, Raymond R Balise, Daniel J Feaster, William Soares, Gary A Zarkin, LaShawn Glasgow, Emmanuel Oga, John McCarthy, Lauren D'Costa, Rouba Chahine, Steve Gomori, Netrali Dalvi, Shikhar Shrestha, Chad Garner, Aimee Shadwick, Pamela Salsberry, Michael W Konstan, Bridget Freisthler, John Winhusen, Nabila El-Bassel, Jeffrey H Samet, Sharon L Walsh
IMPORTANCE: Buprenorphine significantly reduces opioid-related overdose mortality. From 2002 to 2022, the Drug Addiction Treatment Act of 2000 (DATA 2000) required qualified practitioners to receive a waiver from the Drug Enforcement Agency to prescribe buprenorphine for treatment of opioid use disorder. During this period, waiver uptake among practitioners was modest; subsequent changes need to be examined. OBJECTIVE: To determine whether the Communities That HEAL (CTH) intervention increased the rate of practitioners with DATA 2000 waivers and buprenorphine prescribing...
February 5, 2024: JAMA Network Open